This page contains details about ViiV Healthcare clinical trials. Approved prescribing information must continue to guide appropriate use of ViiV Healthcare medicines. This information may vary from country to country. Before prescribing any product mentioned in this section, Healthcare Professionals should consult prescribing information approved in their country. 

Use the filters below to find out more about ViiV Healthcare clinical trials for dolutegravir/lamivudine, cabotegravir & rilpivirine, fostemsavir and dolutegravir/rilpivirine.

Results:

Showing results for

DOLUTEGRAVIR/LAMIVUDINE
CABOTEGRAVIR & RILPIVIRINE
CABOTEGRAVIR & RILPIVIRINE
DOLUTEGRAVIR/LAMIVUDINE
DOLUTEGRAVIR/LAMIVUDINE
DOLUTEGRAVIR/LAMIVUDINE
DOLUTEGRAVIR/LAMIVUDINE
CABOTEGRAVIR & RILPIVIRINE
FOSTEMSAVIR
DOLUTEGRAVIR/RILPIVIRINE
DOLUTEGRAVIR/RILPIVIRINE

NP-GBL-HVX-WCNT-220013 April 2022